Aug. 3, 2007 — The U.S.
Food and Drug Organization (FDA) has approved first-time ware formulations of isoniazid 100-mg/mL insertion, U.S. Pharmacopeia, in 10-mL multiple-dose vials for the prophylaxis and idiom of tuberculosis; aclometasone dipropionate 0.05% pick, U.S. Pharmacopeia, for the interruption of inflammatory and pruritic manifestations of
corticosteroid-responsive dermatoses in patients aged one year and
older; and fexofenadine HCl 60-mg capsules for the respite of symptoms
of seasonal allergic rhinitis and the care of chronic idiopathic
urticaria in patients aged six age and older.
On July 5, the FDA approved a first-time merchandise style of isoniazid 100-mg/mL shot, U.S.
Pharmacopeia,
in 10-mL multiple-dose vials (made by Sabex 2002, Inc.; marker name
Nydrazid, made by Sandoz Pharmaceuticals, a Novartis company).
Isoniazid intramuscular injectant is indicated for use in the prophylaxis and discourse of tuberculosis.
On July 12, the FDA approved a first-time product expression of aclometasone dipropionate 0.05% toilet articles, U.S. Pharmacopeia, made by Altana, Inc.; trade name name Aclovate, made by GlaxoSmithKline).
Aclometasone dipropionate ointment is indicated for the suspension of inflammatory
and pruritic manifestations of corticosteroid-responsive dermatoses in
patients aged one year and older.
The contraceptive and efficacy of its use for longer than troika weeks
have not been established.
On July 12, the FDA approved a first-time product chemical compound of
fexofenadine HCl 60-mg capsules (made by Barr Laboratories, Inc.; blade
name Allegra, made by Aventis Pharmaceuticals, Inc.).
Fexofenadine capsules are indicated for the help of symptoms associated with
seasonal allergic rhinitis and the communication of uncomplicated skin
manifestations of chronic idiopathic urticaria in adults and children
aged six old age and older.